IL-17, IL-23 Therapies Lead Psoriasis Care - Summary - MDSpire
From the Journals

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

Share

A Cochrane meta-analysis evaluated systemic pharmacologic therapies for moderate to severe plaque psoriasis. Biologic therapies, particularly IL-17 and IL-23 inhibitors, showed the highest rates of achieving significant skin clearance (PASI 90) compared to placebo and other treatments. With data from 160 trials involving 57,611 patients, IL-17 inhibitors were most effective, followed by IL-23 inhibitors. Serious adverse events were rare across treatments, highlighting the efficacy and safety of biologics for short-term disease management, though long-term outcomes remain uncertain.

Original Source(s)

IL-17, IL-23 Therapies Lead Psoriasis Care

  • by Andrea Surnit

  • April 12, 2026

Related Content

Halo Scalp Ring Linked to Scarring Alopecia

Birth-related pressure injury may lead to permanent hair loss when follicular damage occurs

Injectable Targets Décolleté Wrinkles

New indication expands use of injectable biostimulator beyond the face.

Cupping vs UVB: Comparable Psoriasis Outcomes?

Randomized study found no statistically significant differences in disease improvement between treatments over 8 weeks.